(1/2) Happy New Year!! Let's look to 2025. Here are the catalysts for 1Q25, with ones I'm watching in magenta Let me know if I missed your favorite catalyst! $ALLK $ANAB $ARVN $DYN $ELVN $ENSC $GHRS $GLUE $IMVT $JSPR $KROS $LPTX $NMRA $PRAX $RGLS $SLDB $SLNO $VERU $VIGL $VIR

@jq1234t Great call

RT @Sanctuary_Bio: $PLRX just wow Leaks in biotech huh

RT @lifesciencerpt: Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis $P…

RT @thudderwicks: $ALMS -5.6%, $SLRN +8.4% [Biopharmaceutical companies Alumis and ACELYRIN said they have agreed to a merger which will s…

RT @bio_clouseau: FDA as well

@ESG_Biotech If you tank your stock, you can have an even bigger up day

RT @fakepharmabro: $ITCI x $JNJ proxy statement Dec. 6: $JNJ reaches out Dec. 13: $JNJ offers $115/sh Jan. 6: 3 other parties contacted J…

@biotech_bullet Yeah, incredibly tone deaf

@BlaseBio There is no way I'm joining this

RT @CrocsAnalyst: $KURA lmaoooooo

$KURA Slides, but still no data: Data to be presented in 2Q25 at a medical meeting

@CostasAgrios I don't see anything wrong

@biopharmacaster Still reading, these things are massive novels

RT @bio_clouseau: $NVO CB1 has failed its p2 in diabetic kidney disease as well. No mention of further obesity trials in todays PR $CRBP

RT @adamfeuerstein: $AMGN A Phase 1 study of AMG 513 in people living with obesity was placed on clinical hold by the U.S. Food and Drug…

RT @WSJ: Novartis has set a high bar for any potential obesity-treatment acquisition as it scans the market for deals to fill its drug pipe…

RT @adamfeuerstein: Senate Finance Committee vote on advancing RFK Jr. nomination: Cassidy voted Yes 14 Yes 13 No.